Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07157514 | Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML | PHASE2/PHASE3 | NOT YET_RECRUITING | 306 | — | — | Jan 1, 2026 | Feb 1, 2034 | Sep 9, 2025 | - | — |
| Name | Type | Description |
|---|---|---|
| 131I-apamistamab | DRUG | Iodine-131 radiolabeled anti-CD45 monoclonal antibody (apamistamab). Administered IV as a dosimetric dose followed by treatment dose. |
| Fludarabine | DRUG | Fludarabine phosphate, 30 mg/m² IV daily on Days -6 through -2. |
| Cyclophosphamide | DRUG | Cyclophosphamide |
| Total Body Irradiation (TBI) | RADIATION | TBI, 200 cGy on Day -1 prior to HSCT. |
| Allogeneic Hematopoietic Stem Cell Transplant (HSCT) | BIOLOGICAL | Unmodified, G-CSF-mobilized donor stem cells infused on Day 0. |